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Is bioprosthetic leaflet thrombosis a 
trigger to valve degeneration?
Mhairi Katrina Doris, Marc Richard Dweck
Transcatheter aortic valve implantation 
(TAVI) has expanded rapidly as a novel 
therapeutic strategy for patients with 
severe symptomatic aortic stenosis. This 
procedure is already well established in 
patients at intermediate or high risk for 
conventional surgical valve replacement 
and, with multiple studies currently evalu-
ating TAVI in low-risk patients, use of this 
treatment is likely to continue to expand 
worldwide. While long-term outcome 
data are lacking, recent results from the 
Placement of Aortic Transcatheter Valves 
(PARTNER) trial indicated promising 
results at 5 years post-implantation, with 
TAVI valves demonstrating similar haemo-
dynamics to surgical bioprosthetic valves 
and no evidence of structural valve deteri-
oration on echocardiography.1 Despite 
these promising data, long-term TAVI 
durability and the mechanisms leading to 
structural valve degeneration are not fully 
understood. Improving our understanding 
of valve durability and the factors leading 
to TAVI valve deterioration is therefore 
paramount, particularly as we consider 
extending this technology to younger 
patient populations.
In their Heart manuscript, Del Trigo 
et al2 investigate the relationship between 
the use of anticoagulation therapy and 
valve haemodynamic deterioration in over 
2000 patients post-TAVI. In this cohort, 
707 patients were treated with oral antico-
agulation therapy with the most common 
indication being atrial fibrillation. The 
majority received vitamin K antagonists, 
with only a small proportion treated 
with direct oral anticoagulants. At 1 year 
follow-up, a small but significant increase 
in mean transvalvular gradient on trans-
thoracic echocardiography was observed 
in patients not receiving anticoagulation 
(9.8 mm Hg to 10.3 mm Hg) compared 
with post-discharge values. By contrast, 
transvalvular gradients remained stable 
after 1 year in the patients receiving anti-
coagulation (9.4 mm Hg and 9.1 mm Hg). 
Valve haemodynamic deterioration, 
defined as an increase in transvalvular 
gradient of ≥10 mm Hg from hospital 
discharge, had a higher incidence in the 
group not treated with anticoagulation 
compared with those receiving anticoagu-
lation (3.7% vs 0.6%, P<0.001). This was 
observed both in the population as a whole 
and in a propensity-matched cohort.
This study does have some limita-
tions. The cohort largely comprised 
patients with well-functioning valves, 
indeed even those patients diagnosed 
with valve haemodynamic deterioration 
had only mild bioprosthetic stenosis, 
with transvalvular gradients <40 mm Hg. 
As a consequence, there were too few 
adverse clinical events in patients with 
valve haemodynamic deterioration in the 
matched population (n=7) for meaningful 
analysis. Another important limitation is 
that bleeding rates in this cohort were not 
available, and it is therefore not possible 
to balance the apparent benefits of anti-
coagulation on valve durability against the 
risk of major bleeding. Finally, this is not a 
randomised controlled trial and there will 
therefore be both known and unknown 
confounders that might account for the 
observed differences.
Nevertheless, the authors are to be 
congratulated on investigating this 
important area and highlighting the 
intriguing hypothesis that anticoagu-
lation therapy post-TAVI may protect 
against subsequent valve deteriora-
tion. This requires a clear mechanistic 
explanation. Bioprosthetic valve degen-
eration is predominantly driven by 
calcification: how might this be linked 
to antithrombotic therapy? One poten-
tial answer is valve leaflet thrombosis. 
While leaflet thrombosis causing abrupt 
valve failure occurs in just 1% of TAVI 
valves, subclinical valve thrombosis has 
been observed in 7%–10% of implanted 
TAVI valves.3 4 The clinical relevance 
of this imaging observation has to date 
been unclear, but perhaps this is not 
a benign phenomenon, perhaps valve 
leaflet thrombosis acts as a trigger to 
calcification and ultimately TAVI valve 
degeneration (figure 1). This hypothesis 
is supported by the pathophysiology of 
native aortic valve stenosis where valve 
leaflet haemorrhage is associated with 
more rapid valve calcification and disease 
progression.5 The study by Del Trigo 
et al is therefore important because of 
the key mechanistic questions raised. 
In the absence of anticoagulation, do 
bioprostheses with evidence of leaflet 
thrombosis calcify and degenerate more 
quickly? Can histological or imaging 
studies confirm the association between 
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Figure 1 Possible link between bioprosthetic valve thrombosis and calcification. The study by 
Del Trigo et al suggests that anticoagulation may preserve transcatheter aortic valve implantation 
(TAVI) valve haemodynamics. The potential mechanism for this observation is not clear. Concern 
has recently grown regarding the incidence of subclinical leaflet thrombosis (red arrow) in patients 
undergoing TAVI, and it is hypothesised that this may lead to future calcific degeneration of 
bioprosthetic TAVI valves (black arrow). Future research should focus on investigating this possible 
mechanistic link between bioprosthetic leaflet thrombosis and valve calcification/degeneration and 
the role that anticoagulant therapy might play in improving TAVI valve durability. 
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leaflet thrombosis and early calcifica-
tion activity? Are surgical bioprostheses 
also susceptible to similar mechanisms 
of degeneration? Research must now 
focus on gaining a greater understanding 
of the link between valve thrombosis 
and degeneration, with the hope that 
ultimately this will help inform optimal 
management to prolong bioprosthetic 
valve longevity and improve patient 
outcomes.
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